B of A Securities has initiated coverage on Scholar Rock Holding Corp (SRRK) with a Buy rating, signaling its positive assessment of the biotechnology firm's investment potential. This marks the firm's first evaluation of Scholar Rock, which focuses on advancing treatments for neuromuscular diseases and other serious conditions through its proprietary platform.
Headquartered in Cambridge, Massachusetts, Scholar Rock is recognized for its innovative approach to drug development, particularly its product candidate apitegromab, a fully human monoclonal antibody aimed at treating spinal muscular atrophy (SMA). The company's market capitalization stands at $4.0 billion, with a trailing twelve-month earnings per share (EPS) of -2.91.
The announcement highlights a broader consensus among analysts, with 7 Strong Buy, 11 Buy, and 1 Hold ratings as of November 1, 2025. Upcoming earnings are anticipated on August 4, 2026, with an estimated EPS of -0.84 and revenue expectations of $2.0 million. Analyst ratings and price targets provide insights based on extensive research and financial models, although they reflect assumptions that may evolve as new information emerges.
Investors are encouraged to consider various factors, including company fundamentals and industry trends, when making decisions. Analyst views should be one of many inputs rather than the sole basis for investment choices. As the biotech landscape continues to evolve, the reception of Scholar Rock's offerings will be closely monitored by market participants.